This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campbell, K. J. Articles by Perkins, N. D. Search for Related Content PubMed PubMed Citation Articles by Campbell, K. J. Articles by Perkins, N. D.

Cisplatin Mimics ARF Tumor Suppressor Regulation of RelA (p65) Nuclear Factor-B Transactivation

School of Life Sciences, Division of Gene Regulation and Expression, University of Dundee, Dundee, Scotland, United Kingdom

Requests for reprints: Neil D. Perkins, School of Life Sciences, Division of Gene Regulation and Expression, University of Dundee, MSI/WTB Complex, Dow Street, Dundee, DD1 5EH, Scotland, United Kingdom. Phone: 44-1382-345-606; Fax: 44-1382-348-072; E-mail: n.d.perkins{at}dundee.ac.uk.

The RelA (p65) nuclear factor-B (NF-B) subunit can contribute towards tumor cell survival through inducing the expression of a variety of antiapoptotic genes. However, the NF-B response can show great diversity and is not always antiapoptotic. Here, we find that cisplatin, a DNA cross-linking agent and commonly used anticancer compound, does not affect RelA nuclear translocation but modulates its transcriptional activity. Similar to other genotoxic agents, such as daunorubicin and UV light, cisplatin treatment in the U-2 OS osteosarcoma cell line represses RelA activity and inhibits expression of the NF-B antiapoptotic target gene Bcl-x_L. The mechanism through which cisplatin achieves these effects is different to daunorubicin and UV light but shows great similarity to the RelA regulatory pathway induced by the ARF tumor suppressor: cisplatin regulation of RelA requires ATR/Chk1 activity, represses Bcl-x_L but not XIAP expression, and results in phosphorylation of RelA at Thr⁵⁰⁵. In contrast to these results, another chemotherapeutic drug etoposide activates NF-B and induces expression of these target genes. Thus, within a single tumor cell line, there is great heterogeneity in the NF-B response to different, commonly used chemotherapeutic drugs. These observations suggest that it might be possible to minimize the ability of RelA to inhibit cancer therapy by diagnostically predicting the type of chemotherapeutic drug most compatible with NF-B functionality in a tumor cell type. Moreover, our data indicate that at least with respect to RelA, cisplatin functions as an ARF mimic. Other drugs capable of mimicking this aspect of ARF function might therefore have therapeutic potential. (Cancer Res 2006; 66(2): 929-35)

This article has been cited by other articles:

				B. K. Bednarski, X. Ding, K. Coombe, A. S. Baldwin, and H. J. Kim Active roles for inhibitory {kappa}B kinases {alpha} and {beta} in nuclear factor-{kappa}B-mediated chemoresistance to doxorubicin Mol. Cancer Ther., July 1, 2008; 7(7): 1827 - 1835. [Abstract] [Full Text] [PDF]

				B. Benayoun, S. Baghdiguian, A. Lajmanovich, M. Bartoli, N. Daniele, E. Gicquel, N. Bourg, F. Raynaud, M.-A. Pasquier, L. Suel, et al. NF-{kappa}B-dependent expression of the antiapoptotic factor c-FLIP is regulated by calpain 3, the protein involved in limb-girdle muscular dystrophy type 2A FASEB J, May 1, 2008; 22(5): 1521 - 1529. [Abstract] [Full Text] [PDF]

				N. Gupta, J. Delrow, A. Drawid, A. M. Sengupta, G. Fan, and C. Gelinas Repression of B-Cell Linker (BLNK) and B-Cell Adaptor for Phosphoinositide 3-Kinase (BCAP) Is Important for Lymphocyte Transformation by Rel Proteins Cancer Res., February 1, 2008; 68(3): 808 - 814. [Abstract] [Full Text] [PDF]

				R. L. Ferris and J. R. Grandis NF-{kappa}B Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., October 1, 2007; 13(19): 5663 - 5664. [Full Text] [PDF]

				M. Neumann and M. Naumann Beyond I{kappa}Bs: alternative regulation of NF-{kappa}B activity FASEB J, September 1, 2007; 21(11): 2642 - 2654. [Abstract] [Full Text] [PDF]

				B. Yamini, X. Yu, M. E. Dolan, M. H. Wu, D. W. Kufe, and R. R. Weichselbaum Inhibition of Nuclear Factor-{kappa}B Activity by Temozolomide Involves O6-Methylguanine Induced Inhibition of p65 DNA Binding Cancer Res., July 15, 2007; 67(14): 6889 - 6898. [Abstract] [Full Text] [PDF]

				C. Van Waes Nuclear Factor-{kappa}B in Development, Prevention, and Therapy of Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1076 - 1082. [Abstract] [Full Text] [PDF]